<DOC>
	<DOCNO>NCT02184455</DOCNO>
	<brief_summary>The purpose clinical trial perform limit pilot study determine safety feasibility DermGEN treatment non-healing diabetic foot ulcer ( DFU ) . This one-arm prospective study . It hypothesize DermGEN treatment result positive healing outcome significant adverse effect .</brief_summary>
	<brief_title>Feasibility Study DermGEN Diabetic Foot Ulcer Treatment</brief_title>
	<detailed_description>This one-arm prospective study . This study Halifax mirror one participate health care center Toronto , Ontario , Canada centre anticipate enrol 5-10 patient total 15-20 patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>A subject consider eligible participate study follow inclusion criterion satisfy : 1 . Patient document stable Type I II diabetes ( HbA1C &gt; 7.0 within 1 month prior Day 0 ) . 2 . Patient 's ulcer present minimum 2 week Day 0 . 3 . Study ulcer heal &lt; 30 % size 2 week prior Day 0 . 4 . Ulcer area â‰¥1 cm2 prior debridement Day 0 study . 5 . Ulcer extend dermis subcutaneous tissue without exposure muscle , tendon , bone joint capsule . 6 . Ulcer free necrotic debris clinical infection , comprise healthy vascular tissue suitable skin graft Day 0 . 7 . Patient adequate circulation foot evidence palpable pulse pulse detectable Doppler ultrasound , lack visible cyanosis skin border ulcer . 8 . Female patient pregnant time , study . 9 . Patient caregiver ready willing participate comply followup regime . 10 . Patient legal representative read sign Institutional Ethics Review Board approve inform consent form . A subject consider eligible participate study one follow exclusion criterion satisfy : 1 . Evidence gangrene affect foot . 2 . Ulcer Charcot deformity ( fracture dislocation ) . 3 . Ulcer nondiabetic etiology . 4 . Ulcer tunnel sinus tract completely debrided . 5 . Medical condition ( ) Investigator 's opinion make patient inappropriate study 6 . Patient has/had malignant disease remission 5 year 7 . Patient acute chronic hepatitis , cirrhosis , serum albumin &lt; 2.0 gm/dL , alkaline phosphatase LDH twice normal upper limit 8 . Patient receive oral parenteral corticosteroid , immunosuppression cytotoxic agent , anticipated require agent study 9 . Patient receive radiation therapy within 30 day Day 0 study 10 . Patient AIDS infect HIV 11 . Patient participate another study use investigational drug ( ) device within previous 30 day 12 . Obvious clinical sign symptom ongoing cellulitis osteomyelitis 13 . Patient condition seriously compromise ability complete study 14 . Patient known allergy antibiotic , penicillin streptomycin 15 . Patient history bleed disorder 16 . Patient receive elective osseous procedure study foot within 30 day prior screen visit , except patient whose DFU overlie area treat osteomyelitis may include , provide exists suitable base application DermGEN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>Chronic Ulcer</keyword>
	<keyword>Wound Healing</keyword>
	<keyword>Leg</keyword>
</DOC>